Bridgebio Pharma, Inc. (BBIO)

Trade BBIO now with
11/18/2021 7:41:07 AM BridgeBio Pharma Executes Definitive Credit Facility Deal With A Syndicate Of Lenders For Up To $750.0 Mln In Financing
10/29/2021 7:32:44 AM BridgeBio Pharma Collaborates With Columbia University To Develop Therapies For Genetic Diseases And Cancers
10/7/2021 9:20:44 AM BridgeBio Announces Publication Of Data For Best-in-Class SHP2 Inhibitor Designed For Treatment Of Resistant Cancer
9/15/2021 7:33:24 AM BridgeBio Receives FDA Fast Track Designation For Therapy For Treatment Of Limb-girdle Muscular Dystrophy Type 2i
8/5/2021 7:49:57 AM BridgeBio Pharma Q2 Loss/shr Narrows $0.66 From $1.03 Last Year
7/8/2021 7:33:14 AM BridgeBio Pharma Announces Collaborations With Three Academic Research Institutions
3/20/2021 11:42:15 AM BridgeBio Pharma Announces Proof-of-Concept Data Of Encaleret In ADH1 At Endocrine Society’s 2021 Annual Meeting
2/19/2021 7:33:45 AM BridgeBio And ML Bio Solutions Dose First Patient In Phase 2 Trial Of BBP-418 In Limb Girdle Muscular Dystrophy Type 2i
1/26/2021 12:08:03 AM BridgeBio Pharma Prices $650 Mln Of 2.25% Convertible Notes Due 2029 In A Private Offering To Institutional Buyers
1/25/2021 7:12:24 AM BridgeBio Pharma Announces Proposed Offering Of $400 Mln Of Convertible Senior Notes Due 2029
1/25/2021 7:09:47 AM BridgeBio Pharma Announces Proposed Offering Of $400 Mln Convertible Senior Notes
1/4/2021 7:46:05 AM ISS Recommends BridgeBio Pharma, Eidos Therapeutics Stockholders Vote For Proposed Merger
12/23/2020 7:37:58 AM UCSF And BridgeBio Pharma Collaborate To Accelerate Development Of Therapies For Genetic Diseases